Clinical Trial Update: Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SBRT followed by tislelizumab plus cetuximab and irinotecan in previously treated RAS wild-type advanced refractory colorectal cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• SBRT (stereotactic body radiotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN